Recent innovations in artificial intelligence are dramatically accelerating biology and drug development. KAIST researchers have improved text-to-image generative models to generate more creative, novel designs by manipulating internal feature maps without retraining. Concurrently, AI-driven platforms like Fauna Brain integrate internal and public datasets to autonomously identify and prioritize novel drug targets, optimizing R&D efficiency. Companies such as Xaira Therapeutics released large-scale perturbation datasets to support virtual cell modeling, while AlphaDesign uses AI for de novo protein design, heralding a new era of programmable biology.